Division of Preventive Cardiology and Rehabilitation, 1st Department of Medicine, Medical School, University of Pecs, 7624 Pecs, Hungary.
Department of Biochemistry and Medical Chemistry, University of Pecs, Medical School, 7624 Pecs, Hungary.
Int J Mol Sci. 2023 Feb 23;24(5):4405. doi: 10.3390/ijms24054405.
Obesity is a major public health problem worldwide, and it is associated with many diseases and abnormalities, most importantly, type 2 diabetes. The visceral adipose tissue produces an immense variety of adipokines. Leptin is the first identified adipokine which plays a crucial role in the regulation of food intake and metabolism. Sodium glucose co-transport 2 inhibitors are potent antihyperglycemic drugs with various beneficial systemic effects. We aimed to investigate the metabolic state and leptin level among patients with obesity and type 2 diabetes mellitus, and the effect of empagliflozin upon these parameters. We recruited 102 patients into our clinical study, then we performed anthropometric, laboratory, and immunoassay tests. Body mass index, body fat, visceral fat, urea nitrogen, creatinine, and leptin levels were significantly lower in the empagliflozin treated group when compared to obese and diabetic patients receiving conventional antidiabetic treatments. Interestingly, leptin was increased not only among obese patients but in type 2 diabetic patients as well. Body mass index, body fat, and visceral fat percentages were lower, and renal function was preserved in patients receiving empagliflozin treatment. In addition to the known beneficial effects of empagliflozin regarding the cardio-metabolic and renal systems, it may also influence leptin resistance.
肥胖是一个全球性的主要公共卫生问题，它与许多疾病和异常有关，最重要的是 2 型糖尿病。内脏脂肪组织产生了大量的脂肪因子。瘦素是第一个被鉴定的脂肪因子，它在调节食物摄入和代谢方面起着关键作用。钠-葡萄糖协同转运蛋白 2 抑制剂是一种有效的抗高血糖药物，具有多种有益的全身作用。我们旨在研究肥胖和 2 型糖尿病患者的代谢状态和瘦素水平，以及恩格列净对这些参数的影响。我们招募了 102 名患者进行临床研究，然后进行了人体测量、实验室和免疫测定测试。与接受常规抗糖尿病治疗的肥胖和糖尿病患者相比，恩格列净治疗组的体重指数、体脂肪、内脏脂肪、尿素氮、肌酐和瘦素水平显著降低。有趣的是，瘦素不仅在肥胖患者中增加，在 2 型糖尿病患者中也增加。接受恩格列净治疗的患者体重指数、体脂肪和内脏脂肪百分比较低，肾功能得到保留。除了恩格列净在心脏代谢和肾脏系统方面的已知有益作用外，它还可能影响瘦素抵抗。
